The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus

This publication has 50 references indexed in Scilit:

• Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
  New England Journal of Medicine, 2009
• Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
  Hepatology, 2008
• The association of family history of liver cancer with hepatocellular carcinoma: A case-control study in the United States
  Journal of Hepatology, 2008
• The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors
  Antimicrobial Agents and Chemotherapy, 2008
• Antiviral Briefs
  AIDS Patient Care and STDs, 2008
• Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
  Genome Biology, 2008
• Phenotypic Characterization of Resistant Val³⁶Variants of Hepatitis C Virus NS3-4A Serine Protease
  Antimicrobial Agents and Chemotherapy, 2008
• The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
  Published by Elsevier ,2006
• VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells
  Antimicrobial Agents and Chemotherapy, 2006
• Impact of Naturally Occurring Variants of HCV Protease on the Binding of Different Classes of Protease Inhibitors
  Biochemistry, 2006